Literature DB >> 22476807

A randomized, single-blind comparison of the efficacy and tolerability of hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the knee.

Xin Tang1, Fu-Xing Pei, Zong-Ke Zhou, Gang Liu, Bin Shen, Peng-De Kang, Jian Li, Xiao-Dan Zhao, Qi Li, Yong Li.   

Abstract

The aim of this study was to prospectively evaluate the efficacy and tolerability of hyaluronic acid (HA) and meloxicam for the treatment of knee pain due to Kashin-Beck disease (KBD). A total of 162 patients with KBD-based knee pain were randomly assigned to treatment with a 3-week course of HA (n = 80) and a 12-week course of meloxicam (n = 82). Clinical assessments for each patient were made at 0 (baseline), 1, 2, 4, 8, and 12 weeks. The primary efficacy measure was visual analog scale (VAS) pain score. Second efficacy measures comprised the Western Ontario and McMaster Universities (WOMAC) A (pain), B (stiffness), and C (function) scores as well as patients' and physicians' global assessments. Tolerability was evaluated based on adverse events (AEs) and physician reporting. The VAS rapidly decreased in both groups over 12 weeks. The VAS improvement observed in HA group was lower at week 1 (p = 0.001) but better at weeks 8 and 12 (p < 0.001) than the meloxicam group, which were supported by the secondary variables of WOMAC A (p = 0.001) and WOMAC C (p < 0.001) scores and the global assessments of the patients and their physicians (p = 0.020 and 0.003, respectively). No serious AEs were reported, and the overall incidence of AEs among patients treated with meloxicam was higher than in patients treated with HA (p = 0.012). This study suggests that intra-articular injection of HA and administration of oral meloxicam should be efficacious and well tolerated in the treatment of knee pain due to KBD; the onset of action of meloxicam was faster than that of HA, whereas HA therapy resulted in a more prolonged increasing improvement of symptoms than meloxicam. In addition, HA treatment was likely superior to meloxicam with respect to tolerability. Other randomized double-blind studies are needed to confirm the findings of our open-label study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476807     DOI: 10.1007/s10067-012-1979-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

Review 1.  WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire.

Authors:  Nicholas Bellamy
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

Review 3.  The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials.

Authors:  W Zhang; J Robertson; A C Jones; P A Dieppe; M Doherty
Journal:  Ann Rheum Dis       Date:  2008-06-09       Impact factor: 19.103

Review 4.  Review of clinical trials and benefit/risk ratio of meloxicam.

Authors:  A Barner
Journal:  Scand J Rheumatol Suppl       Date:  1996

5.  Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients.

Authors:  Rui Luo; Gang Liu; Wei Liu; Fuxing Pei; Zongke Zhou; Jian Li; Bin Shen; Pengde Kang; Qibing Xie; Xin Ma
Journal:  Int Orthop       Date:  2010-06-13       Impact factor: 3.075

6.  Kashin Beck Disease: more than just osteoarthrosis: a cross-sectional study regarding the influence of body function-structures and activities on level of participation.

Authors:  Karin Schepman; Raoul H H Engelbert; Milanka M Visser; Changlong Yu; Rien de Vos
Journal:  Int Orthop       Date:  2010-06-11       Impact factor: 3.075

Review 7.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Bryan; A Fry-Smith; G Harris; R S Taylor
Journal:  Health Technol Assess       Date:  2008-04       Impact factor: 4.014

8.  Articular cartilage metabolism in patients with Kashin-Beck Disease: an endemic osteoarthropathy in China.

Authors:  J Cao; S Li; Z Shi; Y Yue; J Sun; J Chen; Q Fu; C E Hughes; B Caterson
Journal:  Osteoarthritis Cartilage       Date:  2007-10-22       Impact factor: 6.576

9.  The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone.

Authors:  M E Adams; M H Atkinson; A J Lussier; J I Schulz; K A Siminovitch; J P Wade; M Zummer
Journal:  Osteoarthritis Cartilage       Date:  1995-12       Impact factor: 6.576

10.  A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis.

Authors:  J A Wojtulewski; M Schattenkirchner; P Barceló; X Le Loët; P J Bevis; E Bluhmki; M Distel
Journal:  Br J Rheumatol       Date:  1996-04
View more
  9 in total

1.  Reliability and validation of the joint dysfunction index as a new assessment instrument for therapeutic efficacy for Kashin-Beck disease.

Authors:  Fang-Fang Yu; Chuan-Tao Xia; Hua Fang; Di-Miao Wang; Xiong Guo
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

2.  Hyaluronic acid and glucosamine sulfate for adult Kashin-Beck disease: a cluster-randomized, placebo-controlled study.

Authors:  Chuan-Tao Xia; Fang-Fang Yu; Feng-Ling Ren; Hua Fang; Xiong Guo
Journal:  Clin Rheumatol       Date:  2014-11-12       Impact factor: 2.980

3.  Total knee arthroplasty in elderly patients with severe Kashin-Beck disease of the knee.

Authors:  Xin Tang; Zong-Ke Zhou; Bin Shen; Peng-De Kang; Jing Yang; Jian Li; Fu-Xing Pei
Journal:  Int Orthop       Date:  2013-12-10       Impact factor: 3.075

4.  The long-term efficacy and tolerability of hyaluronic acid in adult patients with Kashin-Beck disease of the knee.

Authors:  Xin Tang; Zong-Ke Zhou; Gang Liu; Bin Shen; Peng-De Kang; Jian Li; Qi Li; Fu-Xing Pei
Journal:  Clin Rheumatol       Date:  2014-02-13       Impact factor: 2.980

Review 5.  Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations.

Authors:  Jing Han; Weizhuo Wang; Chengjuan Qu; Ruiyu Liu; Wenrong Li; Zongqiang Gao; Xiong Guo
Journal:  Inflamm Res       Date:  2015-08-11       Impact factor: 4.575

Review 6.  Proteoglycan metabolism, cell death and Kashin-Beck disease.

Authors:  Siyuan Li; Junling Cao; Bruce Caterson; Clare E Hughes
Journal:  Glycoconj J       Date:  2012-06-26       Impact factor: 2.916

7.  Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz.

Authors:  Heng Zhang; Ke Zhang; Xianlong Zhang; Zhenan Zhu; Shigui Yan; Tiansheng Sun; Ai Guo; John Jones; R Grant Steen; Bin Shan; Jenny Zhang; Jianhao Lin
Journal:  Arthritis Res Ther       Date:  2015-03-10       Impact factor: 5.156

8.  The efficacy and safety of intra-articular injection of hyaluronic acid in the knee and physical therapy agents to treat Kashin-Beck disease: A prospective interventional study.

Authors:  Pinglin Yang; Xiong Guo; Xijing He; Quanjin Zang; Guoyu Wang; Peng Xu; Weizhuo Wang
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

9.  Total hip replacement in adult patients with severe Kashin-Beck disease of the hip.

Authors:  Xin Tang; Jing Zhu; Zongke Zhou; Bin Shen; Pengde Kang; Fuxing Pei; Jian Li
Journal:  BMC Musculoskelet Disord       Date:  2016-07-15       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.